Inovio Pharmaceuticals Inc - Asset Resilience Ratio
Inovio Pharmaceuticals Inc (INO) has an Asset Resilience Ratio of 20.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read INO total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Inovio Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See INO total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Inovio Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Inovio Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.24 Million | 20.52% |
| Total Liquid Assets | $14.24 Million | 20.52% |
Asset Resilience Insights
- Good Liquidity Position: Inovio Pharmaceuticals Inc maintains a healthy 20.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Inovio Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Inovio Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Inovio Pharmaceuticals Inc (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Inovio Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.00% | $28.30 Million | $113.20 Million | -51.62pp |
| 2023-12-31 | 76.62% | $130.98 Million | $170.95 Million | +17.32pp |
| 2022-12-31 | 59.30% | $206.67 Million | $348.53 Million | -7.28pp |
| 2021-12-31 | 66.57% | $330.17 Million | $495.94 Million | +36.76pp |
| 2020-12-31 | 29.81% | $160.91 Million | $539.77 Million | -16.97pp |
| 2019-12-31 | 46.78% | $67.34 Million | $143.95 Million | +2.89pp |
| 2018-12-31 | 43.88% | $57.54 Million | $131.11 Million | -11.47pp |
| 2017-12-31 | 55.35% | $103.64 Million | $187.24 Million | +6.06pp |
| 2016-12-31 | 49.30% | $85.63 Million | $173.71 Million | +0.03pp |
| 2015-12-31 | 49.27% | $105.36 Million | $213.84 Million | +8.99pp |
| 2014-12-31 | 40.27% | $53.08 Million | $131.79 Million | +18.86pp |
| 2013-12-31 | 21.41% | $18.91 Million | $88.29 Million | +3.62pp |
| 2012-12-31 | 17.80% | $8.03 Million | $45.14 Million | -3.25pp |
| 2011-12-31 | 21.05% | $12.86 Million | $61.11 Million | +17.76pp |
| 2010-12-31 | 3.29% | $1.85 Million | $56.07 Million | -13.50pp |
| 2009-12-31 | 16.80% | $13.54 Million | $80.63 Million | -25.94pp |
| 2007-12-31 | 42.74% | $17.00 Million | $39.78 Million | +1.85pp |
| 2006-12-31 | 40.89% | $14.70 Million | $35.95 Million | -1.42pp |
| 2001-12-31 | 42.31% | $2.81 Million | $6.63 Million | +17.87pp |
| 2000-12-31 | 24.43% | $2.81 Million | $11.49 Million | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more